- Home
- AHG vs AMRN Comparison
AHG vs AMRN Comparison
Compare AHG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | AMRN |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 287.9M |
| IPO Year | 2017 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AHG | AMRN |
|---|---|---|
| Price | $0.87 | $14.31 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 8.3K | ★ 79.6K |
| Earning Date | 08-14-2025 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $0.80 | $12.96 |
| 52 Week High | $2.50 | $20.90 |
Technical Indicators
Market Signals| Indicator | AHG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 53.65 |
| Support Level | N/A | $13.59 |
| Resistance Level | $1.61 | $14.55 |
| Average True Range (ATR) | 0.08 | 0.51 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 9.48 | 52.55 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.